Balance Sheet
Accounts PayablesAssetsBuildingsCash & Current InvestmentsCash & EquivalentsCommon EquityConstruction in ProgressCurrent AssetsCurrent Deferred RevenueGoodwillGoodwill & IntangiblesIntangiblesInventoryLand & ImprovementsLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsMinority InterestNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Growth Metrics
Income Statement
Others
Ratios

Bristol Myers Squibb (BMYMP) Other Accumulated Expenses (2018 - 2025)

Historic Other Accumulated Expenses for Bristol Myers Squibb (BMYMP) over the last 15 years, with Q4 2025 value amounting to $17.6 billion.

  • Bristol Myers Squibb's Other Accumulated Expenses fell 300.67% to $17.6 billion in Q4 2025 from the same period last year, while for Dec 2025 it was $17.6 billion, marking a year-over-year decrease of 300.67%. This contributed to the annual value of $17.6 billion for FY2025, which is 300.67% down from last year.
  • Bristol Myers Squibb's Other Accumulated Expenses amounted to $17.6 billion in Q4 2025, which was down 300.67% from $19.3 billion recorded in Q3 2025.
  • Bristol Myers Squibb's Other Accumulated Expenses' 5-year high stood at $19.3 billion during Q3 2025, with a 5-year trough of $12.4 billion in Q1 2022.
  • For the 5-year period, Bristol Myers Squibb's Other Accumulated Expenses averaged around $15.2 billion, with its median value being $14.9 billion (2022).
  • In the last 5 years, Bristol Myers Squibb's Other Accumulated Expenses crashed by 1919.37% in 2021 and then soared by 2248.27% in 2024.
  • Bristol Myers Squibb's Other Accumulated Expenses (Quarter) stood at $14.0 billion in 2021, then grew by 4.4% to $14.6 billion in 2022, then grew by 8.9% to $15.9 billion in 2023, then increased by 14.11% to $18.1 billion in 2024, then fell by 3.01% to $17.6 billion in 2025.
  • Its Other Accumulated Expenses was $17.6 billion in Q4 2025, compared to $19.3 billion in Q3 2025 and $17.4 billion in Q2 2025.